Clinical Trial Update: Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tumor response time of palbociclib in combination with AI in real-world Chinese patients with breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• AI (aromatase inhibitor)
• Palbociclib (palbociclib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Breast Neoplasms | Phase 2 | Status: UNKNOWN